The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study

The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study

Abstract Background Coronavirus disease 2019 (COVID-19) causes life-threatening pneumonia. Convalescent plasma therapy (CPT) is expected to be the effective COVID-19 treatment for passive immunity. The high neutralizing antibodies titer of CPT is needed to prove the benefit in early developed severe...

Full description

Bibliographic Details
Main Authors: Nuttakant Nontawong, Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Mana Boonpratoom, Nawin Krailassiri, Chayaporn Boonkhum, Kamonwan Soonklang, Yong Poovorawan, Nithi Mahanonda
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Annals of Clinical Microbiology and Antimicrobials
Subjects:
COVID-19
Convalescent plasma
Severe COVID-19
Mortality
Online Access:https://doi.org/10.1186/s12941-022-00542-2

Internet

https://doi.org/10.1186/s12941-022-00542-2

Similar Items